Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Biomarkers for Alzheimer’s disease and Parkinson’s disease.

BIOMARKAPD

Neurodegenerative disorders, represented mostly by Alzheimer's disease (AD) and Parkinson's disease (PD), are characterised by progressive neuronal impairment and death. In spite of the brain's known capacity for regeneration, lost neurons generally cannot be replaced. Therefore, drugs aimed at inhibiting neurodegenerative processes are likely to...

Funding Programme
Start Date
End Date
Total Funding
€ 449 066

Blood Biomarker-based Diagnostic Tools for Early Stage Alzheimer’s Disease

BBDiag

Alzheimer’s disease (AD) affects more than 7 million people in Europe and this figure is expected to double every 20 years. Despite intensive efforts, no disease-modifying treatments or preventive strategies are available. The lack of specific, sensitive and minimally invasive diagnostics to identify people with early-stage AD to be included in...

Funding Programme
Start Date
End Date
Total Funding
€ 3 465 708
European Countries Involved

Blood microRNAs ADAM10-target: novel diagnostic and prognostic biomarkers for Alzheimer's disease by electrochemical sensors

mirADAM

ADAM10 (A Disintegrin and Metalloprotease 10), the main α-secretase of the non-amyloidogenic cleavage of the amyloid precursor protein (APP), is a common player in Type 2 diabetes (T2D) and Alzheimer´s disease (AD). ADAM10 levels are altered in platelets, plasma, serum, and CSF of elderly with AD, suggesting its potential role as an AD biomarker...

Funding Programme
Start Date
End Date
Total Funding
€ 90 576
European Countries Involved

blood Proteins for early Discrimination of dEmentias

bPRIDE

Dementia is a group of disorders characterized by severe memory loss ultimately impairing daily life activities. Major forms are Alzheimer’s disease, Lewy body dementia, and frontotemporal dementia. Each dementia type is caused by different biological factors and therefore requires a specific treatment targeting these factors. To develop effective...

Funding Programme
Start Date
End Date
Total Funding
€ 1 800 000
European Countries Involved

Brain Endothelium - TARgeted Gene therapy to improve Aβ clearance in Alzheimer’s Disease

BEndTarG

Alzheimer disease (AD) is the most common cause of dementia (60-80% of cases) with a prevalence near 50 million people. There is no cure available and there are only two classes of approved drugs that are effective in treat some of the cognitive symptoms and potentially delay the clinical decline. Despite the considerable progress achieved in the...

Funding Programme
Start Date
End Date
Total Funding
€ 165 312
European Countries Involved

Brain health in Atherosclerosis and Cardiovascular risk in mid-life, a PESA-Brain project

BrainAtCardio

This project aims to investigate the early associations between cardiovascular health and Alzheimers disease (AD) pathology, with a focus on subclinical atherosclerosis (SCAth) and cardiovascular risk factors (CVRFs), in a large cohort of asymptomatic, middle-aged individuals. The overarching objective is to determine how cardiovascular health in...

Funding Programme
Start Date
End Date
Total Funding
€ 194 074
European Countries Involved

Calcium-Sensing Receptor (CaSR): Therapeutics for Non-Communicable Diseases

CaSR Biomedicine

The calcium sensing receptor (CaSR) is a class C Gprotein-coupled receptor that plays a pivotal role in systemic calcium metabolism by regulating parathyroid hormone secretion and urinary Ca excretion. Abnormal CaSR function is implicated in calciotropic disorders, and in non-calciotropic disorders such as Alzheimer’s disease (AD), cardiovascular...

Funding Programme
Start Date
End Date
Total Funding
€ 3 657 195

Clot formation as a potential diagnostic tool and therapeutic target for Alzheimer's disease

ADVASCULATURE

Alzheimer’s disease (AD) is the leading cause of dementia in the elderly. Accumulating evidence links AD with vascular risk factors. These correlations, together with profound alterations of cerebrovascular structure and function present in AD, suggest a “vascular hypothesis”, where vascular pathology eventually leads to neurodegeneration and...

Funding Programme
Start Date
End Date
Total Funding
€ 230 037
European Countries Involved

CLOUD-BASED MULTIMODAL NEUROIMAGING PLATFORM

Neurocloud

One of the main socioeconomics challenges to be faced in the next decades will be the prevalence of neurodegenerative diseases (such as Alzheimer’s and Parkinson’s) due to population ageing. Today, diagnosis, treatment and monitoring of such illness is complex, a laborious process completed by a limited set of Neurologist experts who need to...

Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

Cognition, ageing, and bilingualism: Investigating age-related changes in bilingual language switching and use.

CAB

Older adults show difficulties with bilingual language processing and switching compared to younger adults. For example, they need more time to switch between languages and show more cross-language intrusions. Language problems have not only been found for healthy older adults, but also in patients with dementia and Parkinson’s disease. Language...

Funding Programme
Start Date
End Date
Total Funding
€ 158 122
European Countries Involved

Cognitive Rehabilitation Gamming System (cRGS): a novel Virtual Reality-based system for the conjunctive training of stroke-derived cognitive impairments

cRGS

The cDAC ERC Advanced project develops and validates a theory of consciousness and its application to the understanding and alleviation of its deficits. cDAC proposes that consciousness is a virtualization memory system that monitors and optimizes the real-time control of perception, cognition and action realized in a multi-layered architecture...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

COMORBIDITY MECHANISMS UTILIZED IN HEALTHCARE

COMMUTE

The COVID pandemic can be seen as an experiment done with the entirety of humankind (as almost everybody has been or will get infected with SARS-CoV-2). It will therefore have the best coverage over the widest variation possible and is therefore ideally suited to study the effects of infections with SARS-CoV-2 on large quantities of heterogeneous...

Funding Programme
Start Date
End Date
Total Funding
€ 7 280 986
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).